talazoparib (Talzenna) plus enzalutamide (Xtandi): FDA status

Under review Indication: HRR gene altered metastatic castration sensitive prostate cancer. Company: Pfizer.

Regulatory history

All products in the FDA Tracker

Loading today's edition…